- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01522547
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)
November 6, 2019 updated by: Celgene
A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 In Subjects With Sickle Cell Disease
The purpose of the study is to determine the maximum tolerated dose, safety and effect on induction of fetal hemoglobin of pomalidomide in patients with Sickle Cell Disease.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201-2097
- Karmanos Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 18 to 60 years, inclusive, at the time of signing the informed consent form
- Clinically significant Sickle Cell Disease (SCD) documented as Sickle Cell Anemia or Sickle Beta-Zero Thalassemia
- Clinically significant SCD defined as at least 1 documented pain episode per year averaged over the past 3 years or one episode of active leg ulcers, priapism, or acute chest syndrome over the past 3 years
- Failed to achieve at least an absolute 5% increase in hemoglobin F while taking Hydroxyurea (HU) or unable to tolerate HU as described by the treating physician and may include but is not limited to lack of efficacy (such as people who have continued to have pain episodes more than 2 times a year or who have had acute chest or multiorgan failure syndromes or an episode of priapism), or other severe side effects while on HU (severe side effects include significant myelosuppression; skin cancer; or cytotoxicity evidenced by gastrointestinal symptoms, dermatological reactions, hepatic enzyme elevations, pulmonary fibrosis or neurological disturbances), or refusal of hydroxyurea therapy by the informed patient
- Able to adhere to the study visit schedule and other protocol requirements
- Females must be surgically sterile (post hysterectomy or bilateral oophorectomy) or naturally postmenopausal for at least 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months)
- Male subjects must agree to use a latex condom during any sexual contact with females of child bearing potential (FCBP) during study drug treatment, during dose interruptions, and for at least 28 days following discontinuation of study drug even if they have undergone a successful vasectomy. Counseling about the requirement for latex condom use during sexual contact with FCBP and the potential risks of fetal exposure must be conducted at a minimum of every 28 days.
- Male subjects must agree to abstain from donating semen or sperm while taking study drug and for 28 days after stopping study drug.
- Both males and females must agree to abstain from donating blood while taking study drug and for 28 days after stopping study drug.
- Both males and females must agree that they will not share study drug and will be counseled about the potential risks of fetal exposure.
Exclusion Criteria:
- Known positive status for human immune virus (HIV), Hepatitis B; or acute/chronic, active Hepatitis C
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- Females of childbearing potential, pregnant or lactating females
- Any condition, including the presence of laboratory abnormalities, which place the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Subjects unlikely to comply with birth control, medication dosing, or study visit requirements
- Subjects with severe or life threatening, active, unresolved infections
Any of the following laboratory abnormalities derived from the Screening Visit:
- Platelet count or white blood cell count (WBC) less than the lower limit of normal (LLN)
- Total hemoglobin less than or equal to 6.0 g/dL
- Hemoglobin A (HbA) from transfusion greater than 20% at baseline
- Creatinine greater than Upper Limit of Normal (ULN)
- Alanine Aminotransferase / Serum Glutamic Pyruvic Transaminase (ALT/SGPT) greater than 3 x ULN
- Total bilirubin greater than 10 mg/dL
- Subjects on a chronic transfusion program
- History of non-catheter related Deep Vein Thrombosis (DVT) or stroke
- Chronic symptomatic constipation
- History of cancer (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for at least three years.
- Use of agents that can induce fetal hemoglobin within 90 days (three months) of Day 1 (i.e. HU, butyrates, decitabine, 5-azacytidine, or erythropoietin)
- Use of experimental drug or treatment within 30 days of the first dose of study drug
- History of allergic reaction to thalidomide or lenalidomide
- Prior desquamating (blistering) rash while taking thalidomide or lenalidomide
- Greater than or equal to a Grade 2 neuropathy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1: 0.5 mg pomalidomide
0.5 mg pomalidomide orally daily for 84 days
|
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Names:
|
EXPERIMENTAL: Cohort 2: 1.0 mg pomalidomide
1.0 mg pomalidomide orally daily for 84 days
|
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Names:
|
EXPERIMENTAL: Cohort 3: 2.0 mg pomalidomide
2.0 mg pomalidomide orally daily for 84 days
|
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Names:
|
EXPERIMENTAL: Cohort 4: 3.0 mg pomalidomide
3.0 mg pomalidomide orally daily for 84 days
|
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Names:
|
EXPERIMENTAL: Cohort 5: 4.0 mg pomalidomide
4.0 mg pomalidomide orally daily for 84 days
|
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: Up to 84 days
|
Maximum Tolerated Dose
|
Up to 84 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Up to 169 days
|
Type, frequency, and severity of adverse events, and relationship of adverse events to pomalidomide
|
Up to 169 days
|
Absolute fetal hemoglobin change
Time Frame: UP to 169 days
|
Percent of subjects with an absolute increase of 5% in percent fetal hemoglobin levels during study treatment
|
UP to 169 days
|
% total hemoglobin
Time Frame: Up to 169 days
|
Percent change in total hemoglobin from baseline to highest level
|
Up to 169 days
|
Rate of total hemoglobin change
Time Frame: Up to 169 days
|
Rate of change of total hemoglobin from baseline to highest level
|
Up to 169 days
|
Inflammation markers and cytokines
Time Frame: Up to 169 days
|
Change in serum inflammation markers and cytokines from baseline, during and at end of study treatment
|
Up to 169 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 1, 2007
Primary Completion (ACTUAL)
October 1, 2012
Study Completion (ACTUAL)
December 1, 2013
Study Registration Dates
First Submitted
January 27, 2012
First Submitted That Met QC Criteria
January 27, 2012
First Posted (ESTIMATE)
January 31, 2012
Study Record Updates
Last Update Posted (ACTUAL)
November 8, 2019
Last Update Submitted That Met QC Criteria
November 6, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Pomalidomide
Other Study ID Numbers
- CC-4047-SCD-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia, Sickle Cell
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
National Institute of Diabetes and Digestive and...RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell TraitUnited States
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSickle Cell Anemia in ChildrenUganda
-
Al-Neelain UniversityUniversity of KhartoumUnknownSickle Cell Anemia in ChildrenSudan
Clinical Trials on pomalidomide
-
Kirby InstituteActive, not recruitingHigh Grade Squamous Intra-epithelial Lesion (HSIL)Australia
-
Amsterdam UMC, location VUmcNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
CelgeneTerminatedSystemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, SystemicUnited States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
-
Stanford UniversityCelgene CorporationWithdrawnPulmonary FibrosisUnited States
-
CelgeneCompletedMultiple MyelomaCanada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
-
CelgeneCompletedMultiple MyelomaBelgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Second Hospital of Shanxi Medical UniversityCompleted